. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:18.766888"^^ . . . "for COVID-19 therapy" . "(414, 422)" . "considered" . "498" . "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . "(414, 422)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-2" . "camostat" . "therapy" . "RSA" . "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" . "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" . . .